. ANXA2 depleted cells show higher proliferation rate compared to matched control cells following EGF treatment. MDA-MB-231 ANXA2 shRNA2 (KD) and scramble (scr); HT1080 ANXA2 shRNA2 (KD) and scramble (scr); or A549 ANXA2 shRNA2 (KD) and scramble (scr) cells were serum starved for 16 h, after what they were either not treated (NT) or treated with 15 nM of EGF for 24 h. Cell proliferation was determined by using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer's instructions. Error bars represent the standard deviation obtained from three independent experiments. Statistical analysis was evaluated using two-tailed Student's t-test. In every case a p-value of less than 0.05 (*), less than 0.01(**) and 0.001 (***) was considered statistically significant. Figure S3 . Analysis of ANXA2 shRNAs cancer cell lines. HT1080 (left lanes); MDA-MB-231 (middle lanes) or A549 (right lanes) ANXA2 shRNA1; ANXA2 shRNA2 or ANXA2 scramble cell lines were plated in 60 mm plates for 48 h. After what cells were lysed and 20 µg of each protein extract was subjected to SDS-PAGE, transferred onto nitrocellulose membranes and analyzed by western blotting with the antibodies indicated. Results are representative of three independent experiments (N = 3). Figure S4 . Analysis of intracellular ROS levels in ANXA2 depleted versus control cells. HT1080 ANXA2 shRNA2 (KD) and scramble (scr); MDA-MB-231 ANXA2 shRNA2 (KD) and scramble (scr); or A549 ANXA2 shRNA2 (KD) and scramble (scr) cells were incubated with 50 µM of DCF-DA for 30 min at 37 °C, 5% CO2. After what fluorescence was measured (Excitation: 488 nm, Emission: 535 nm) using a fluorometer plate reader. Error bars represent the standard deviation obtained from three independent experiments. Statistical analysis was evaluated using two-tailed Student's t-test. In every case a p-value of less than 0.05 (*), less than 0.01 (**) and 0.001 (***) was considered statistically significant. Figure S8 . Immunofluorescence staining of ANXA2 and PRDX2 in colon clinical samples. Tumor clinical samples were flash frozen and sectioned using a cryostat. Samples were then fixed with methanol and immuno-stained with the antibodies indicated, followed by immunofluorescence staining with secondary antibodies (ANXA2-green; PRDX2-red). (a) ANXA2 and PRDX2 staining; (b) ANXA2 and hnRNP A2/B1 (nuclear marker) staining; (c) ANXA2 and S100A10 staining. Table S2 . List of shRNA and CRISPR/Cas9 plasmids. Plasmids were constructed by cloning the following double stranded oligos into the backbone plasmids indicated. Table S4 . qRT-PCR primers list.
Plasmid

Gene Forward Primer
Reverse Primer PRDX2 5′-GTC CTT CGC CAG ATC ACT GT-3′ 5 ′-ACG TTG GGC TTA ATC GTG TC-3′ EPHX2 5′-GTG TTC ATT GGC CAT GAC TG-3′ 5 ′-CTC AGT GAC CAT CCT GCT GA-3′ SrxN1 5′-GGG CTG GAC CCA CTG TAG TA-3′ 5 ′-CCA GGG ACT CTT GGT TTT CA-3′ NUDT1 5′-AAG AAG GAG AGA CCA TCG AGG AT-3′ 5 ′-TGC AGG GCG TCC ACT GT-3′ CATALASE 5′-TGA CCG AGA GAG AAT TCC TGA-3′ 5 ′-CCT TTG CCT TGG AGT ATT TGG-3′ SCARA-3 5′-TGC GGA TTC TTT ACC TCT TCC T-3′ 5 ′-TCT TCG GAG AGA GAG TCC ACT TTT-3′ TxnRD1 5′-TTC ACC TCA GTT TTC TTC ACT CC-3′ 5 ′-TCT GCC CTC CTG ATA AGC AA-3′ TxnRD2 5′-GGT GGA CTA CGT GGA ACC TT-3′ 5 ′-TCT GCC ATC TTC CTC CAG TCA-3′ RPLP0 5′-AGA CAA TGT GGG CTC CAA GCA GAT-3′ 5 ′-GCA TCA TGG TGT TCT TGC CCA TCA-3′
